Beijing Aeonmed ,北京谊安  www.aeonmed.com
谊安医疗是中国领先的手术室、ICU设备研发制造厂商及医疗系统解决方案提供商之一。
自成立以来，谊安始终以临床需求为导向，致力于临床医疗设备和解决方案的研究。目前，谊安业务涵盖麻醉与手术支持、急救与危重症治疗、医疗工程设备三大产品组合以及层流感控、环境及设备配置、集中供气、流程质控、信息一体化等五大医疗系统解决方案。
2008年，谊安麻醉机取得重大突破，获得美国FDA 510K许可，成功登陆美国本土市场。目前，谊安已有几十项产品获得欧盟CE认证，销往全球110多个国家和地区。尤为自豪的是，175台Shangrila510 急救呼吸机在众多国际品牌中脱颖而出，被国际奥组委选定为2008年北京奥运会31个比赛场馆现场急救站指定呼吸机品牌并圆满完成了这项光荣而艰巨的任务。
自主创新造就了谊安的竞争优势。目前，谊安已经获得授权和申报的专利达400余项，发明专利200余项，并保持每年100多项的增长 。
“产品可靠，服务贴心”是谊安对客户的承诺，“真诚守护生命”是谊安的神圣使命。面对未来，谊安人正以饱满的创新激情践行自己的使命，实现成为“手术室和ICU的运营专家”的企业愿景。


北京谊安医疗系统股份有限公司
地址：北京市丰台区丰台科学城航丰路4号 谊安大厦
邮编：100070
电话：010－83681616
传真：010－63718989
 

市 场 部：aeonmedvoice@aeonmed.com
顾客服务部：service@aeonmed.com
销售管理部：info@aeonmed.com
采 购 部：purchase@aeonmed.com
人力资源：aeonmedhr@aeonmed.com

国际业务：int@aeonmed.com

Established in 2001, Aeonmed has around 800 employees till September 2010. Under the brand name of Aeonmed symbolizing “Safety, Quality, Value, and Innovation”, the company finished its strategy adjustment in 2009: repositioning of “The Operation Expert of OR & ICU” based on previous “The Expert of Anesthesia and Respiration”. Currently, Aeonmed becomes a comprehensive medical care supplier in OR and ICU areas providing three product portfolios and five total solutions.

Domestically, Aeonmed has built its sales and distribution network all over the country through which the company provides service on time to more than 8,000 hospitals covering provincial, municipal, county and township levels. Internationally, 20 products of Aeonmed received EU CE certificates already. Matching international standards and request, Aeonmed’s products have been sold to more than 90 countries and/or areas. In 2008, one anesthesia machine designed and manufactured by Aeonmed was successfully launched in the US market after FDA510K filing.

Innovation is the corporate core competence of the company. Totally, Aeonmed has been awarded or applied 354 patents including 242 invention patents.

Currently, Aeonmed work enthusiastically towards company’s vision “The Operation Expert of OR & ICU”. With inner people’s efforts and outside support from our valued customers & partners, this target will be reached in near future.